KHẢO SÁT KẾT QUẢ TRIỂN KHAI CHƯƠNG TRÌNH ĐIỀU TRỊ F0 TẠI NHÀ

Abstract

Introduction: Molnupiravir is an oral antiviral drug that received Use Authorization in Vietnam for the treatment of mild COVID-19. Objective: Determine the rate of patients recovering and reducing symptoms after using the F0 treatment package at home and some factors related to the effectiveness of using the drug package. Methods: Longitudinal study. Results: 400 F0 after 5 days of taking the drug the number of positive patients remained 35 patients, the number of negative or positive (CT ≥ 30) increased to 365 patients (p < 0.05). The proportion of patients with negative or positive test results (CT ≥ 30) after 5 days accounted for 91.2%. The cure rate after using the drug pack accounted for 99.85%, there was no patient death. 100% have negative test results (recover) after finishing the treatment period. There was relationship between age groups (OR=2.7); Underlying medical conditions (OR=3.0) with positive test result (CT < 30) with negative and positive (CT ≥ 30) after 5 days of taking the drug (p < 0.05). Conclusion: Molnupiravir caused reduction in the risk of hospitalization or death in mild COVID-19 patients, molnupiravir was also found to be well tolerated and safe without any major adverse events on use.